Final Program

SUNDAY • MAY 15 57
P773
P774
P775
P776
P777
A41
b2-Adrenoceptor-Mediated Gene Expression In Human Airway
Epithelial Cells: Can a Given Long-Acting b2-Adrenoceptor
Agonist Induce Gene Expression with Different Operational
Efficacies?/D. Yan, O. Hamed, N. Antony, R. Newton, M.A.
Giembycz, Calgary, Canada, p.A1497
Antagonistic Interactions Between TGFb1 and Nrf2 in the
Alveolar Epithelium of HIV-1 Transgenic Rats/X. Fan, B.
Staitieh, R. Raynor, D.M. Guidot, Atlanta, GA, p.A1498
Human Rhinovirus-Induced Responses Differ Between Two
Models of Well-Differentiated Human Bronchial Epithelial
Cells/S. Warner, D. Proud, Calgary, Canada, p.A1499
Increased Expression of a Proliferation-Inducing Ligand
(APRIL) in Lung Leukocytes and Alveolar Epithelial Cells in
COPD Patients with Non Small Cell Lung Cancer: A Possible
Link Between COPD and Lung Cancer?/F. Polverino, M.
Laucho-Contreras, J. Rojas Quintero, M.J. Divo, V. Pinto-Plata,
L.M. Sholl, J.P. De-Torres, B.R. Celli, C.A. Owen, Boston, MA,
p.A7785
Mitochondrial DNA Released by Endotracheal Intubation Is
Linked to Neutrophil Activation and Sore Throat Pain/C. Puyo,
D. Peruzzi, A. Earhart, M. Ibrahim, A.E. Gelman, St. Louis, MO,
p.A7786
THEMATIC POSTER SESSION
THE SPECTRUM COPD CARE: FROM
IDENTIFICATION TO POLICY
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area B, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator:
P170
P171
P172
P173
M.J. Joo, MD, PhD, Chicago, IL
Peer Researchers’ Knowledge, Confidence and Self-Reported
Readiness to Administer Spirometry After Training/C.B.
Charron, T. Kaur, T. Rose, K. Florence, S. Pakhale, Ottawa,
Canada, p.A1500
Role of Spoken Languange in Education of Inhaler Technique:
Differences Among English and Non-English Speaking
Patients/H. Landau, S.M. Hon, N. Al-Naamani, R. Tsacoyianis, C.
Balbuena, S. Kher, Boston, MA, p.A1501
Chronic Obstructive Pulmonary Disease Access to Community
Health/C. Landon, R. Higgins, H. Hansen, S. White-Wood,
Ventura, CA, p.A1502
Diagnosis and Management of Chronic Obstructive Pulmonary
Disease Care in Urban Versus Rural Veterans Affairs
Clinics/E.J. Swanson, A.D. Westanmo, T.S. Rector, K.L. Rice,
P.G. Duane, Minneapolis, MN, p.A1503
P174 Do We Confirm the “O” in COPD?/D.A. DeLapp, A. Hotz, D.
Bricker, Dayton, OH, p.A1504
P175
Facilitator:
P176
P177
P178
P179
P180
P181
Facilitator:
P182
P183
P184
P185
P186
P187
Chronic Obstructive Pulmonary Disease: How Accurate Is the
Diagnosis in Hospitalized Patients?/H. Wu, S. Beygi, A.
Medinger, Washington, DC, p.A1505
R.G. Barr, MD, DrPH, New York, NY
Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in
Chronic Obstructive Pulmonary Disease (COPD) Patients at
Discharge After an Exacerbation- Interim Findings from a
Prospective Study/G.G. Sharma, D.A. Mahler, V. Mayorga, K.
Deering, V. Ganapathy, Galveston, TX, p.A1506
The Distribution of COPD Categories in General Practice
According to GOLD 2011 Classification in Russian
Federation/K. Piontkovskaya, V.V. Arkhipov, M. Miravitlles, D.E.
Arkhipova, E. Stukalina, I. Osipova, A. Ipatov, Moscow, Russian
Federation, p.A1507
Prevalence of Chronic Obstructive Pulmonary Disease (COPD)
Among Patients Previously Treated for Pulmonary
Tuberculosis (PTB) in Manila: A Multi-Center Study (PreCOPT
Study)/C.B. Gulay, H.S. Delfin, J. Benedicto, L. Fernandez, R.
Pagcatipunan Jr, Manila, Philippines, p.A1508
Use of Artificial Intelligence Versus Traditional Methods in the
Diagnosis of COPD/A.R. Bastidas Goyes, D. Botero Rosas, L.P.
Fajardo Latorre, C. Labrador Lopez, 140013, Colombia, p.A1509
Empirically Identifying Clinical COPD Subphenotypes and
Their Stability/D. Blagev, S. Rea, D.S. Collingridge, Murray, UT,
p.A1510
Diagnosis Differences for Pulmonary Restrictive Defects
Between NHANESIII and GLI12 Predictions on Caucasian
Populations/O.J. Linares, M. Hegewald, R.L. Jensen, J.
Hankinson, A. Morris, Salt Lake City, UT, p.A1511
A.S. Gershon, MD, MSc, Toronto, Canada
Prevalence of Age-Adjusted Comorbid Diseases and
Implications for Survival in a COPD Population in a Primary
Care Accountable Care Organization/A. Kleppinger, J. Lynch,
K.M. Fox, J.R. Davis, M. DePietro, Farmington, CT, p.A1512
Mortality Outcomes of Long-Term Domiciliary Non-Invasive
Ventilation in Stable Chronic Obstructive Pulmonary Disease
with Chronic Type 2 Respiratory Failure/P. Lee, E. Innes, J.
Qian, C. Chen, A.T. Ng, Sydney NSW, Australia, p.A1513
A Systematic Review and Correlation and Regression Analysis
of Rescue Medication Use with Standard COPD Endpoints/Y.S.
Punekar, S. Sharma, A. Pahwa, J. Takyar, I. Naya, P.W. Jones,
Brentford, United Kingdom, p.A1514
How Does Chronic Obstructive Pulmonary Disease
Management Affect Patient-Centered Health Outcomes and
Cardiovascular Risk - The Command Study/M. Bhutani, D. Fuhr,
I.J. Andersson, R. Damant, B.H. Rowe, R. Leigh, M. Stickland,
Edmonton, Canada, p.A1515
Disease Severity as a Determinant of Health Status in Patients
with Chronic Obstructive Pulmonary Disease/N. Malik, K.
Chima, Lahore, Pakistan, p.A1516
Steroid Use in Inpatient Management of COPD
Exacerbation/G.W. Heckert, M. Stephen, Philadelphia, PA,
p.A1517
SUNDAY MORNING
ATS 2016 • San Francisco